Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c
Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.